SALT LAKE CITY, March 29, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Eric Santa as its new Chief Growth Officer. In this role, he will be responsible for accelerating growth initiatives and building commercial capabilities, and digital platforms to better serve patients and healthcare providers, while driving increased market demand for the company’s portfolio of existing and new products and services.
Santa, who reports directly to Paul J. Diaz, president and CEO of Myriad Genetics, brings proven healthcare expertise spanning consumer and digital businesses, as well as commercial transformation, portfolio management, and new growth channels. He previously served as Chief Revenue Officer of Rally Health, Inc., a division of Optum within UnitedHealth Group, where he spearheaded consumer digital health strategies and online mobile solutions that make it easier for consumers to take charge of their health. He led key Rally business functions, including sales for payer, provider, and employer markets. He also was responsible for client management and partner relationships while opening new markets, optimizing business lines, and expanding into growing areas such as telehealth.
At Myriad, Santa will lead strategic initiatives that advance the company’s growth plans, expand its reach, and drive customer-centric commercial capabilities across sales, marketing, and digital platforms. He will lead key enabling functions including enterprise marketing, digital, brand and marketing communications. In addition, he will lead the company’s efforts to use its deep reservoir of patient data to further enhance its genetic insights and expand the company’s commercial reach.
As part of Santa’s team, Jeff Borcherding has been promoted to senior vice president and Chief Marketing Officer, responsible for the company’s integrated product marketing initiatives designed to increase test volumes and revenue. Borcherding previously was general manager for GeneSight®, leading sales, marketing, customer services, and medical affairs.
Strengthening Diversity, Equity and Inclusion
Myriad announced that Gwendolyn F. Turner is joining the company to lead diversity, equity and inclusion (DEI) initiatives and support the company’s broader commitment to addressing environmental, social and governance matters (“ESG”). Turner previously served as head of equity, inclusion, diversity and talent engagement at Northwest Permanente/Kaiser Permanente. She will report to Jayne Hart, Chief People Officer.
In her new position, Turner will be responsible for further strengthening Myriad Genetics’ commitment to diversity, equity and inclusion, applying her leadership and functional experience to support socially inclusive product development, talent development, and related internal and external practices. As part of her responsibilities, Turner will drive company-wide programs that promote a strong inclusive culture. She also will oversee Myriad’s Women’s Leadership Group and DEI Forum, comprised of hundreds of employees from a range of backgrounds, businesses and functions.
“The addition of highly experienced, proven leaders from other innovative companies and organizations across the healthcare ecosystem is a significant component of our transformation and growth plan. At the same time, we are coupling new external perspectives with high-performing talent from within Myriad so we can leverage a full range of experiences and perspectives,” said Diaz. “We are fortunate to have a senior executive of Eric’s caliber joining us to spearhead new growth initiatives together with proven marketing leaders like Jeff. As part of our ongoing commitment to teammate engagement, ESG and diversity, equity and inclusion, we will benefit from Gwen’s deep experience as a global human resources and diversity leader who will significantly advance our efforts in an area that is at the heart of our purpose of improving health and wellbeing for all.”
About Myriad Genetics
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where genetic testing can significantly improve patient care and lower healthcare costs. For more information on how Myriad fulfills its purpose, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to accelerating growth initiatives, building commercial capabilities and digital platforms to better serve patients and healthcare providers, and driving increased market demand for the company’s portfolio of existing and new products and services; increasing test volumes and revenue; promoting a strong inclusive culture; and the Company’s strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
|Media Contact: Jared Maxwell||Investor Contact: Scott Gleason|
|(801) 505-5027||(801) 584-1143|